Related coverage linked through entity extraction aliases.
Apr 08, 2026
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Mar 25, 2026
An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.
Mar 09, 2026
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
Mar 03, 2026
New research warns AI pathology systems may use statistical shortcuts rather than biological signals, while a clinical trial shows stereotactic radiation improves quality of life for patients with multiple brain metastases compared to whole brain radiation.
Feb 24, 2026
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
Feb 15, 2026
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant metastatic colorectal cancer, driving shares up 19.7%.
Feb 13, 2026
Immunotherapy is increasingly being used before and after surgery across seven cancer types, while the global immunotherapy drugs market experiences significant growth driven by advances in biotechnology and targeted therapies.
Feb 13, 2026
The FDA approved Optune Pax, a wearable Tumor Treating Fields device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The approval marks the first new treatment for this indication in nearly 30 years.
